Practice
Featured experience
Bristol Myers Squibb $13 billion notes offering
The investment-grade offering comprised nine tranches
Cisco Systems $13.5 billion notes offering
The investment-grade offering comprises seven tranches of notes
Galderma Group CHF2.3 billion ($2.6 billion) IPO
We advised Galderma on its IPO
Novartis $3.7 billion notes offering
We advised Novartis on the investment-grade debt offering
Strategy $2 billion convertible notes offering
The convertible notes are due 2030
iQIYI $350 million convertible notes offering and concurrent private repurchases
We advised iQIYI on the transactions
Incora emerges from chapter 11
We advised an ad hoc group of secured noteholders in connection with Incora’s chapter 11 proceedings
Eastman Chemical $250 million notes offering
The investment-grade notes are due 2029
Solid Biosciences $200 million stock and pre-funded warrants offering
The stock is listed on the Nasdaq Global Select Market
PPL $2 billion at-the-market offering
We advised PPL on the offering
InflaRx $30 million offering of ordinary shares and pre-funded warrants
The ordinary shares are listed on the Nasdaq Global Market
Avianca senior secured notes offering and exchange offer and consent solicitation
The transactions included a $1 billion senior secured notes offering and a $1.1 billion exchange offer and consent solicitation
NeuroPace $74.75 million follow-on offering
The stock is listed on the Nasdaq Global Market
Oculis Holding $100 million follow-on equity offering
The shares are listed on the Nasdaq Global Market and the Nasdaq Iceland Main Market